Diltiazem Dosing for Supraventricular Tachycardia (SVT) Management

Initial IV Bolus Dosing

• The American Heart Association recommends administering diltiazem 0.25 mg/kg (approximately 15-20 mg for average adults) IV over 2 minutes, followed by a second dose of 0.35 mg/kg (20-25 mg) after 15 minutes if needed, for acute SVT management 1, 2
• A second dose of 0.35 mg/kg (20-25 mg) may be given 15 minutes after the first dose if no therapeutic response occurs, as recommended by the American College of Cardiology 1

Maintenance Infusion

• The American Heart Association suggests starting continuous infusion at 5 mg/hour, titrating up to 15 mg/hour based on heart rate response, for maintenance therapy 1, 2

Critical Contraindications

• The American College of Cardiology advises against using diltiazem in patients with pre-excited atrial fibrillation/flutter (WPW syndrome or accessory pathways conducting to ventricles), as it may accelerate ventricular response and cause hemodynamic collapse 1, 2
• Diltiazem is contraindicated in patients with second or third-degree AV block without a functioning pacemaker, as recommended by the American Heart Association 1, 2
• The American College of Cardiology recommends avoiding diltiazem in patients with decompensated heart failure or severe LV dysfunction, due to its negative inotropic effects 1, 2
• Diltiazem is contraindicated in patients with hypotension or cardiogenic shock, as stated by the American Heart Association 2
• The American College of Cardiology advises against using diltiazem in patients with sick sinus syndrome without a pacemaker 2

Monitoring Requirements

• The American Heart Association recommends continuous ECG monitoring during diltiazem administration 1
• Frequent blood pressure measurements are necessary throughout the infusion, as suggested by the American College of Cardiology 1
• The American Heart Association emphasizes the importance of having defibrillator and resuscitation equipment immediately available during diltiazem administration 2

Clinical Pearls and Pitfalls

• The American College of Cardiology recommends using adenosine as the first-line treatment for stable PSVT, but diltiazem may be used when adenosine fails or is contraindicated 2
• The American Heart Association advises against combining diltiazem with beta-blockers acutely, as this can cause profound bradycardia and heart block 1, 2
• In hemodynamically unstable patients, the American College of Cardiology recommends skipping medications entirely and proceeding directly to synchronized cardioversion 2

Diltiazem Use in Acute Paroxysmal Supraventricular Tachycardia (PSVT): Evidence‑Based Recommendations

Contraindications & Safety Precautions

• Pre‑excited atrial fibrillation/flutter (e.g., Wolff‑Parkinson‑White syndrome) is an absolute contraindication to diltiazem because the drug may accelerate ventricular response and precipitate hemodynamic collapse or ventricular fibrillation. 3, 4
• Hemodynamically unstable patients with PSVT should receive immediate synchronized cardioversion rather than diltiazem. 3, 5
• Decompensated heart failure or severe left‑ventricular dysfunction contraindicates diltiazem due to its negative inotropic effect that can worsen cardiac output. 3

Treatment Algorithm

• First‑line therapy: Perform vagal maneuvers (e.g., Valsalva, carotid sinus massage) before any medication. 5, 4
• Third‑line pharmacologic option: If adenosine is ineffective or contraindicated, diltiazem is an appropriate alternative for rate control or conversion. 3, 5
• Last‑resort therapy: When all pharmacologic agents fail, proceed to synchronized cardioversion. 3, 5, 4

Rhythm Confirmation Prior to Diltiazem

• Rule out ventricular tachycardia or pre‑excited atrial fibrillation/flutter before administering diltiazem, as the drug can exacerbate these arrhythmias. 3, 4

Intravenous Diltiazem Use in Acute Supraventricular Tachycardia – Evidence‑Based Recommendations

First‑Line Assessment

• In hemodynamically stable adults presenting with acute supraventricular tachycardia, vagal maneuvers (e.g., Valsalva, carotid sinus massage, or facial ice pack) should be attempted before any drug therapy. 6
• Adenosine is recommended as the preferred first‑line pharmacologic agent because it terminates atrioventricular nodal re‑entrant tachycardia (AVNRT) in approximately 95 % of cases. 6

Contraindication Screening

• Prior to administering diltiazem, clinicians must exclude ventricular tachycardia and pre‑excited atrial fibrillation/flutter on the electrocardiogram; giving diltiazem in these rhythms can precipitate hemodynamic collapse. 6

Adverse‑Effect Profile

• Hypotension is the most common dose‑related adverse effect, occurring in roughly 18 %–42 % of patients receiving intravenous diltiazem. 7
• Bradycardia may develop, especially in patients with underlying conduction system disease; severe cases should be treated with atropine or temporary pacing. 7

Management of Hemodynamically Unstable Patients

• In patients who are hemodynamically unstable, pharmacologic therapy (including diltiazem) should be omitted and immediate synchronized cardioversion performed. 6

Oral Maintenance Therapy After Acute Conversion

These oral dosing recommendations apply to patients who have achieved rhythm conversion and require ongoing rate control.